Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Welgene Biotech Co's Operating Income for the
three
months ended in Jun. 2026 was NT$-1.9 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-2.9 Mil.
Warning Sign:
Welgene Biotech Co Ltd had lost money in 75% of the time over the past 12quarters.
Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Welgene Biotech Co's annualizedROC % for the quarter that ended in Jun. 2026 was -1.71%.
Welgene Biotech Co's annualizedROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -0.36%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.
Be Aware
Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Welgene Biotech Co Operating Income Related Terms
Welgene Biotech Co Operating Income Historical Data
* Premium members only.
The historical data trend for Welgene Biotech Co's Operating Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.
Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-2.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Welgene Biotech Co (ROCO:6661) has a Operating Income of NT$-2.9 Mil as of Jun. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Welgene Biotech Co and its competitors.
Is Welgene Biotech Co's Operating Income too high?
Welgene Biotech Co's current Operating Income is NT$-2.9 Mil. Overall, Welgene Biotech Co has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Welgene Biotech Co's Operating Income compare to TMO and DHR?
Welgene Biotech Co's Operating Income of NT$-2.9 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Medical Diagnostics & Research company?
A good Operating Income depends on the Medical Diagnostics & Research industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Welgene Biotech Co and its competitors. Welgene Biotech Co's current Operating Income is NT$-2.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Welgene Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Welgene Biotech Co (ROCO:6661) is currently considered Possible Value Trap. The stock's GF Value™ is NT$29.10, compared to a current price of NT$17.20 — trading 40.9% below its estimated fair value. The current Operating Income is NT$-2.9 Mil. Welgene Biotech Co's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Welgene Biotech Co (ROCO:6661), the current Operating Income is NT$-2.9 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Welgene Biotech Co (ROCO:6661) Overvalued in 2026?
Based on GuruFocus' analysis, Welgene Biotech Co stock appears to be undervalued.
The current stock price of NT$17.20 is trading 40.9% below its estimated GF Value™ of NT$29.10.
GuruFocus considers Welgene Biotech Co to be Possible Value Trap.
Key valuation signals for ROCO:6661:
Operating Income: NT$-2.9 Mil
GF Value™: NT$29.10 vs. price of NT$17.20 (40.9% below fair value)
No single metric tells the full story. See the ROCO:6661 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Welgene Biotech Co Ltd is engaged in providing genetic and biotechnology testing services and related products. Its offerings include next-generation sequencing (NGS) services, DNA microarray and PCR-based testing solutions, biotechnology reagents, diagnostic products, and laboratory instruments. The company also engages in the trading of medical and biotechnology equipment.
71GF Score
Get the complete analysis for ROCO:6661
Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6661 has been successfully added to your 
